Institution
Autonomous University of Barcelona
Education•Cerdanyola del Vallès, Spain•
About: Autonomous University of Barcelona is a education organization based out in Cerdanyola del Vallès, Spain. It is known for research contribution in the topics: Population & Context (language use). The organization has 37833 authors who have published 80514 publications receiving 2321142 citations. The organization is also known as: Universitat Autònoma de Barcelona & Computer Vision Center.
Topics: Population, Context (language use), Medicine, Cancer, Transplantation
Papers published on a yearly basis
Papers
More filters
••
University Hospital of Basel1, University Medical Center Groningen2, University of California, San Diego3, University of Glasgow4, Monash University5, University of Warwick6, University of Brescia7, University of Paris8, University of Zurich9, University of Ljubljana10, National and Kapodistrian University of Athens11, University of Cyprus12, University of Belgrade13, Autonomous University of Barcelona14, University of Otago15, National University of Singapore16, Harvard University17
TL;DR: Screening with NPs for the early detection of relevant cardiac disease including left ventricular systolic dysfunction in patients with cardiovascular risk factors may help to identify patients at increased risk, therefore allowing targeted preventive measures to prevent HF.
Abstract: Natriuretic peptide [NP; B-type NP (BNP), N-terminal proBNP (NT-proBNP), and midregional proANP (MR-proANP)] concentrations are quantitative plasma biomarkers for the presence and severity of haemodynamic cardiac stress and heart failure (HF). End-diastolic wall stress, intracardiac filling pressures, and intracardiac volumes seem to be the dominant triggers. This paper details the most important indications for NPs and highlights 11 key principles underlying their clinical use shown below. NPs should always be used in conjunction with all other clinical information. NPs are reasonable surrogates for intracardiac volumes and filling pressures. NPs should be measured in all patients presenting with symptoms suggestive of HF such as dyspnoea and/or fatigue, as their use facilitates the early diagnosis and risk stratification of HF. NPs have very high diagnostic accuracy in discriminating HF from other causes of dyspnoea: the higher the NP, the higher the likelihood that dyspnoea is caused by HF. Optimal NP cut-off concentrations for the diagnosis of acute HF (very high filling pressures) in patients presenting to the emergency department with acute dyspnoea are higher compared with those used in the diagnosis of chronic HF in patients with dyspnoea on exertion (mild increase in filling pressures at rest). Obese patients have lower NP concentrations, mandating the use of lower cut-off concentrations (about 50% lower). In stable HF patients, but also in patients with other cardiac disorders such as myocardial infarction, valvular heart disease, atrial fibrillation or pulmonary embolism, NP concentrations have high prognostic accuracy for death and HF hospitalization. Screening with NPs for the early detection of relevant cardiac disease including left ventricular systolic dysfunction in patients with cardiovascular risk factors may help to identify patients at increased risk, therefore allowing targeted preventive measures to prevent HF. BNP, NT-proBNP and MR-proANP have comparable diagnostic and prognostic accuracy. In patients with shock, NPs cannot be used to identify cause (e.g. cardiogenic vs. septic shock), but remain prognostic. NPs cannot identify the underlying cause of HF and, therefore, if elevated, must always be used in conjunction with cardiac imaging.
379 citations
••
TL;DR: In this paper, the authors explore the institutional factors that encourage opportunity entrepreneurship in order to achieve higher rates of economic growth and suggest that institutions may not have an automatic effect, as is typically assumed in growth models.
379 citations
••
Sapienza University of Rome1, Innsbruck Medical University2, German Center for Neurodegenerative Diseases3, Radboud University Nijmegen4, Erasmus University Rotterdam5, Imperial College London6, Newcastle University7, Palacký University, Olomouc8, University of Belgrade9, Autonomous University of Barcelona10, University of Marburg11, University of Zagreb12, Charles University in Prague13, University College London14, University of Tartu15, French Institute of Health and Medical Research16
TL;DR: A Task Force was convened by the EFNS/MDS‐ES Scientist Panel on Parkinson's disease and other movement disorders to systemically review relevant publications on the diagnosis of PD.
Abstract: Background
A Task Force was convened by the EFNS/MDS-ES Scientist Panel on Parkinson's disease (PD) and other movement disorders to systemically review relevant publications on the diagnosis of PD.
Methods
Following the EFNS instruction for the preparation of neurological diagnostic guidelines, recommendation levels have been generated for diagnostic criteria and investigations.
Results
For the clinical diagnosis, we recommend the use of the Queen Square Brain Bank criteria (Level B). Genetic testing for specific mutations is recommended on an individual basis (Level B), taking into account specific features (i.e. family history and age of onset). We recommend olfactory testing to differentiate PD from other parkinsonian disorders including recessive forms (Level A). Screening for pre-motor PD with olfactory testing requires additional tests due to limited specificity. Drug challenge tests are not recommended for the diagnosis in de novo parkinsonian patients. There is an insufficient evidence to support their role in the differential diagnosis between PD and other parkinsonian syndromes. We recommend an assessment of cognition and a screening for REM sleep behaviour disorder, psychotic manifestations and severe depression in the initial evaluation of suspected PD cases (Level A). Transcranial sonography is recommended for the differentiation of PD from atypical and secondary parkinsonian disorders (Level A), for the early diagnosis of PD and in the detection of subjects at risk for PD (Level A), although the technique is so far not universally used and requires some expertise. Because specificity of TCS for the development of PD is limited, TCS should be used in conjunction with other screening tests. Conventional magnetic resonance imaging and diffusion-weighted imaging at 1.5 T are recommended as neuroimaging tools that can support a diagnosis of multiple system atrophy (MSA) or progressive supranuclear palsy versus PD on the basis of regional atrophy and signal change as well as diffusivity patterns (Level A). DaTscan SPECT is registered in Europe and the United States for the differential diagnosis between degenerative parkinsonisms and essential tremor (Level A). More specifically, DaTscan is indicated in the presence of significant diagnostic uncertainty such as parkinsonism associated with neuroleptic exposure and atypical tremor manifestations such as isolated unilateral postural tremor. Studies of [123I]MIBG/SPECT cardiac uptake may be used to identify patients with PD versus controls and MSA patients (Level A). All other SPECT imaging studies do not fulfil registration standards and cannot be recommended for routine clinical use. At the moment, no conclusion can be drawn as to diagnostic efficacy of autonomic function tests, neurophysiological tests and positron emission tomography imaging in PD.
Conclusions
The diagnosis of PD is still largely based on the correct identification of its clinical features. Selected investigations (genetic, olfactory, and neuroimaging studies) have an ancillary role in confirming the diagnosis, and some of them could be possibly used in the near future to identify subjects in a pre-symptomatic phase of the disease.
378 citations
••
TL;DR: This work critically assess the potential of experimental therapies targeting α-synuclein, and discusses steps that need to be taken for target validation and drug development.
Abstract: Progressive neuronal cell loss in a small subset of brainstem and mesencephalic nuclei and widespread aggregation of the α-synuclein protein in the form of Lewy bodies and Lewy neurites are neuropathological hallmarks of Parkinson's disease. Most cases occur sporadically, but mutations in several genes, including SNCA, which encodes α-synuclein, are associated with disease development. The discovery and development of therapeutic strategies to block cell death in Parkinson's disease has been limited by a lack of understanding of the mechanisms driving neurodegeneration. However, increasing evidence of multiple pivotal roles of α-synuclein in the pathogenesis of Parkinson's disease has led researchers to consider the therapeutic potential of several strategies aimed at reduction of α-synuclein toxicity. We critically assess the potential of experimental therapies targeting α-synuclein, and discuss steps that need to be taken for target validation and drug development.
377 citations
••
University of Paris1, Paris Descartes University2, Charité3, King Saud University4, Harvard University5, University of Manchester6, Kyushu University7, Vanderbilt University8, University of Freiburg9, University of Debrecen10, Alfaisal University11, University of South Florida12, National Institutes of Health13, University of Oxford14, University of British Columbia15, University of Toronto16, Boston Children's Hospital17, National Defense Medical College18, State University of New York Upstate Medical University19, Dalhousie University20, Royal Children's Hospital21, François Rabelais University22, Cambridge University Hospitals NHS Foundation Trust23, University College London24, Istanbul University25, Autonomous University of Barcelona26, University of Barcelona27, University of Zurich28, Medical College of Wisconsin29, Katholieke Universiteit Leuven30
TL;DR: IRAK-4 and MyD88 deficiencies predispose patients to recurrent life-threatening bacterial diseases, such as invasive pneumococcal disease in particular, in infancy and early childhood, with weak signs of inflammation.
377 citations
Authors
Showing all 38202 results
Name | H-index | Papers | Citations |
---|---|---|---|
Adrian L. Harris | 170 | 1084 | 120365 |
Yang Gao | 168 | 2047 | 146301 |
Alvaro Pascual-Leone | 165 | 969 | 98251 |
David R. Jacobs | 165 | 1262 | 113892 |
Donald G. Truhlar | 165 | 1518 | 157965 |
J. S. Lange | 160 | 2083 | 145919 |
Joseph Wang | 158 | 1282 | 98799 |
José Baselga | 156 | 707 | 122498 |
Stephen J. Chanock | 154 | 1220 | 119390 |
Michael A. Matthay | 151 | 998 | 98687 |
David D'Enterria | 150 | 1592 | 116210 |
G. Eigen | 148 | 2188 | 117450 |
Inkyu Park | 144 | 1767 | 109433 |
Teruki Kamon | 142 | 2034 | 115633 |
Detlef Weigel | 142 | 516 | 84670 |